Regenxbio Inc reports results for the quarter ended December 31 - Earnings Summary
13/03/2025 21:02
Regenxbio Inc RGNX.OQ reported a quarterly adjusted loss of $1.01 per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-1.43. The mean expectation of ten analysts for the quarter was for a loss of $1.15 per share. Wall Street expected results to range from $-1.34 to -46 cents per share. Revenue fell 4.5% to $21.21 million from a year ago; analysts expected $23.75 million. Regenxbio Inc's reported EPS for the quarter was a loss of $1.01. The company reported a quarterly loss of $51.19 million. Regenxbio Inc shares had fallen by 13.7% this quarter. FORECAST CHANGES The mean earnings estimate of analysts had fallen by about 2.3% in the last three months. In the last 30 days, one analyst negatively revised an earnings estimate RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" Wall Street's median 12-month price target for Regenxbio Inc is $28.50 This summary was machine generated from LSEG data March 13 at 09:01 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Dec. 31 2024 | -1.15 | -1.01 | Beat |
| Sep. 30 2024 | -1.12 | -1.17 | Missed |
| Jun. 30 2024 | -1.29 | -1.05 | Beat |
| Mar. 31 2024 | -1.26 | -1.33 | Missed |